Home / Pharmaceutical company intelligence
Maxitech Pharma (Pvt) Ltd. site mark
Pharmaceutical company intelligence

Maxitech Pharma (Pvt) Ltd.

Private pharmaceutical manufacturer · Karachi · Pakistan

Karachi-based pharmaceutical manufacturer with cGMP-oriented manufacturing and a diversified branded portfolio.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation22 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date27 Jul 2026Newest effective date among published current price records
Corporate profile evidence4 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Legal / official name
Maxitech Pharma (Pvt.) Ltd.
Company type
Private pharmaceutical manufacturer
Address
E-178, S.I.T.E., Super Highway Phase-II, Karachi, Pakistan
Phone
+92 21 36411932
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
88%
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000851 118 linked products · source seen 22 Sep 2026 View source ↗
Corporate profile source ledger Contact Page Url source ↗ Logo Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx121public portfolio records represented
REG100unique registrations represented
IDX117indexed MedInfoBase presentations
SRC3additional source-observed presentations
R+1registry-only registrations
VER0registry-verified exact registrations
PKR114current validated price records
G45generic molecules in indexed catalogue
DF10dosage-form groups
TA10therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage94%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage91%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixMaxitech Pharma (Pvt) Ltd.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/maxitech-pharma-pvt-ltdGenerated 22 Sep 2026Anti-infectives87 · 74%Dermatology8 · 7%Cardiovascular6 · 5%Vitamins, minerals & nutrition3 · 3%Fluids & supportive care3 · 3%Oncology & immunology3 · 3%Gastrointestinal & hepatology3 · 3%Other therapeutic areas4 · 3%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioMaxitech Pharma (Pvt) Ltd.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/maxitech-pharma-pvt-ltdGenerated 22 Sep 2026117presentationsTablet41 · 35%Injection31 · 26%Capsule18 · 15%Suspension9 · 8%Cream5 · 4%Infusion4 · 3%Other forms9 · 8%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionMaxitech Pharma (Pvt) Ltd.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/maxitech-pharma-pvt-ltdGenerated 22 Sep 2026107comparable productsBelow peer median44 · 41%Near peer median47 · 44%Above peer median16 · 15%Company median price position-4.3%Lowest-price equivalents11Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsMaxitech Pharma (Pvt) Ltd.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/maxitech-pharma-pvt-ltdGenerated 22 Sep 2026Neutro Pharma (Pvt.) Ltd.,31 shared69% overlapPharmasol (Pvt) Ltd.29 shared64% overlapEpharm Laboratories29 shared64% overlapM/s. Genix Pharma (Pvt) Ltd.28 shared62% overlapValor Pharmaceuticals28 shared62% overlapNovaMed Pharmaceuticals(Pvt.)Ltd28 shared62% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives87 products · 74%
Dermatology8 products · 7%
Cardiovascular6 products · 5%
Vitamins, minerals & nutrition3 products · 3%
Fluids & supportive care3 products · 3%
Oncology & immunology3 products · 3%
Gastrointestinal & hepatology3 products · 3%
Endocrine & metabolic2 products · 2%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antivirals18 products · 15%
Third-generation cephalosporins17 products · 15%
Fluoroquinolone antibacterials9 products · 8%
Macrolide antibacterials7 products · 6%
Antifungals6 products · 5%
Oxazolidinone antibacterials5 products · 4%
Antimalarials5 products · 4%
First-generation cephalosporins4 products · 3%
Formulation footprint

Dosage forms

Tablet41 products
Injection31 products
Capsule18 products
Suspension9 products
Cream5 products
Infusion4 products
Lotion3 products
Drops2 products
Ointment2 products
Sachet2 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 MaxribRibavirin 15presentations 400 mg, 500 mg, 600 mg · Tablet #2 KOCEFANCeftriaxone 7presentations 1 g, 2 g, 250 mg, 500 mg · Injection #3 LinzoLinezolid 5presentations 100 mg/5 mL, 200 mg /100 mL, 400 mg, 600 mg · Suspension, Injection, Tablet #4 ReflazinCiprofloxacin 5presentations 100 mg/50 mL, 200 mg/100 mL, 250 mg, 250 mg/5 mL · Infusion, Tablet #5 MixoCefixime 4presentations 100 mg/5 mL, 200 mg, 200 mg/5 mL, 400 mg · Suspension, Capsule #6 TigasorAcitretin 4presentations 10 mg, 25 mg · Capsule
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median4441% of comparable products
Near market median47within ±5% of median
Above market median1615% of comparable products
Lowest-price equivalents11ties included
Company median price position -4.3% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
MEFINTIN-EZ 80 80 mg + 480 mgArtemether + Lumefantrine · Tablet · 8's PKR 62.63/tablet-42.5% vs market median Obtrude 1.5 gCefuroxime · Injection · 1's PKR 206.49/vial/unit-40.8% vs market median MAXIZOLE Topical 2 %Miconazole · Cream · 20gm PKR 4.80/g-37.4% vs market median Glycocin 20 mg/2 mLGentamicin · Injection · 2mlx5's PKR 7.77/mL-34.5% vs market median Reflazin 200 mg/100 mLCiprofloxacin · IV infusion · 1's PKR 151.83/vial/unit-31.5% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 31shared generics Pharmasol (Pvt) Ltd.257 products · 102 generics 29shared generics Epharm Laboratories144 products · 67 generics 29shared generics M/s. Genix Pharma (Pvt) Ltd.297 products · 97 generics 28shared generics Valor Pharmaceuticals219 products · 97 generics 28shared generics NovaMed Pharmaceuticals(Pvt.)Ltd187 products · 62 generics 28shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers97Distinct registrations among indexed, published, presentation-validated products only
Verified price observations117
Products with a verified price117
Products with multiple price observations0
Source records with multiple versions116
Latest portfolio source check22 Sep 2026
Latest effective price date27 Jul 2026
Latest source observation22 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

100 unique registration(s) · 117 indexed presentation(s) · 3 additional source-observed presentation(s) · 1 registry-only registration(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Bactocan Fluconazole 150 mg Capsule 4's 083723 PKR 995.04 PKR 248.76/capsule 6% below median
Bactocan Fluconazole 150 mg Capsule 1's 083723 PKR 275.27 PKR 275.27/capsule Near median
Bactocan Fluconazole 50 mg/5 mL Suspension 35ml 083751 PKR 418.88 PKR 11.97/mL Near median
Cefenas Cephalexin 500 mg Capsule 12's 096080 PKR 388.30 PKR 32.36/capsule 5% above median
Cefenas Cephalexin 125 mg/5 mL Suspension 60ml 096379 PKR 108.94 PKR 1.82/mL Near median
Cefenas Cephalexin 250 mg/5 mL Suspension 60ml 096380 PKR 188.05 PKR 3.13/mL Near median
CHOLCE-D Cholecalciferol 5 mg Injection 1mlx1's 096046 PKR 213.57 PKR 213.57/mL 14% above median
CHOLCE-D Cholecalciferol 50,000 IU Capsule 100’s 118149 PKR 250.52 PKR 2.51/capsule No comparator
Dimed Betamethasone dipropionate 0.05% Cream 15gm 083737 PKR 72.44 PKR 4.83/g 24% below median
Dimed Betamethasone dipropionate 0.05 % Lotion 60ml 083738 PKR 149.60 PKR 2.49/mL 23% below median
Dimed Betamethasone dipropionate 0.05 % Lotion 20ml 083738 PKR 67.82 PKR 3.39/mL 27% above median
Dimed ointmant Betamethasone 0.05% Ointment 15gm 095187 PKR 72.44 PKR 4.83/g 26% below median
E-Bal Oral rehydration salts (ORS) NaCl 2.6 g + trisodium citrate dihydrate 2.9 g + KCl 1.5 g + dextrose anhydrous 13.5 g Sachet 1's 083748 PKR 19.95 PKR 19.95/sachet No comparator
E-Bal Sodium chloride 2.60 g Sachet 20's 083748 PKR 398.94 PKR 19.95/sachet 23% below median
FOTAXIME Cefotaxime 1 g IV/IM injection 1’s 096382 PKR 285.88 PKR 285.88/vial/unit Near median
FOTAXIME Cefotaxime 250 mg IV/IM injection 1’s 096383 PKR 105.47 PKR 105.47/vial/unit Near median
FOTAXIME Cefotaxime 500 mg IV/IM injection 1’s 096384 PKR 158.95 PKR 158.95/vial/unit Near median
Glycocin Gentamicin 20 mg/2 mL Injection 2mlx5's 096049 PKR 77.66 PKR 7.77/mL 34% below median
Glycocin Gentamicin 40 mg/2 mL Injection 2mlx5's 096050 PKR 116.49 PKR 11.65/mL 24% below median
Glycocin Gentamicin 80 mg/2 mL Injection 2mlx5's 096051 PKR 155.32 PKR 15.53/mL 17% below median
Itrazox Itraconazole 100 mg Capsule 4's 082171 PKR 598.41 PKR 149.60/capsule Near median
IVREA Ivermectin 6 mg Tablet 10's 115910 PKR 402.35 PKR 40.24/tablet 26% below median
IVREA Ivermectin 3 mg Tablet 20's 115911 PKR 485.85 PKR 24.29/tablet 25% below median
JELOCOS Ciclosporin 100 mg Capsule 50's 115830 PKR 11,775.86 PKR 235.52/capsule 22% below median
JELOCOS Ciclosporin 50 mg Capsule 50's 115831 PKR 7,591.45 PKR 151.83/capsule Near median
JELOCOS Ciclosporin 25 mg Capsule 50’s 118148 PKR 2,945.48 PKR 58.91/capsule 22% below median
KEFAMIN Ceftazidime 1 g IV/IM injection 1’s 097036 PKR 456.12 PKR 456.12/vial/unit 6% above median
KEFAMIN Ceftazidime 250 mg IV/IM injection 1’s 097037 PKR 159.64 PKR 159.64/vial/unit Near median
KEFAMIN Ceftazidime 500 mg IV/IM injection 1’s 097038 PKR 242.84 PKR 242.84/vial/unit Near median
KOCEFAN Ceftriaxone 1 g IM injection 1’s 097028 PKR 592.75 PKR 592.75/vial/unit Near median
KOCEFAN Ceftriaxone 1 g IV injection 1’s 097029 PKR 592.75 PKR 592.75/vial/unit Near median
KOCEFAN Ceftriaxone 2 g IV injection 1’s 097030 PKR 830.97 PKR 830.97/vial/unit Near median
KOCEFAN Ceftriaxone 250 mg IM injection 1’s 097032 PKR 186.50 PKR 186.50/vial/unit Near median
KOCEFAN Ceftriaxone 250 mg IV injection 1’s 097033 PKR 186.50 PKR 186.50/vial/unit Near median
KOCEFAN Ceftriaxone 500 mg IM injection 1’s 097034 PKR 313.93 PKR 313.93/vial/unit Near median
KOCEFAN Ceftriaxone 500 mg IV injection 1’s 097035 PKR 313.93 PKR 313.93/vial/unit Near median
Levcin Levofloxacin 500 mg Tablet 10's 083717 PKR 829.80 PKR 82.98/tablet Near median
Levcin Levofloxacin 250 mg Tablet 10's 083718 PKR 498.67 PKR 49.87/tablet Near median
Lideez Lidocaine 1 % Injection 2mlx1's 096052 PKR 12.00 PKR 6.00/mL 114% above median
Linzo Linezolid 400 mg Tablet 12's 083713 PKR 2,912.25 PKR 242.69/tablet 5% above median
Linzo Linezolid 600 mg Tablet 12's 083714 PKR 5,098.44 PKR 424.87/tablet 8% above median
Linzo Linezolid 100 mg/5 mL Suspension 60ml 083750 PKR 698.14 PKR 11.64/mL 6% above median
Linzo Linezolid 100 mg/5 mL Suspension 120ml 083750 PKR 1,326.47 PKR 11.05/mL Near median
Linzo Linezolid 200 mg /100 mL Injection 100ml x1's 096065 PKR 671.76 PKR 6.72/mL No comparator
Maxithro Azithromycin 250 mg Tablet 6's 083704 PKR 299.20 PKR 49.87/tablet 6% above median
Maxithro Azithromycin 500 mg Tablet 6's 083705 PKR 548.55 PKR 91.43/tablet 8% above median
Maxithro Dry powder Azithromycin 200 mg/5 mL Suspension 15ml 083752 PKR 329.12 PKR 21.94/mL Near median
MAXIZOLE Topical Miconazole 2 % Cream 20gm 101013 PKR 96.01 PKR 4.80/g 37% below median
Maxrib Ribavirin 400 mg Tablet 50's 093029 PKR 825.80 PKR 16.52/tablet 8% below median
Maxrib Ribavirin 400 mg Tablet 10's 093029 PKR 179.53 PKR 17.95/tablet Near median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Maxitech Pharma (Pvt) Ltd — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 22, 2026, from https://medinfobase.com/company/maxitech-pharma-pvt-ltd/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.